Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m(...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurol Med Chir (Tokyo)
Asıl Yazarlar: AOKI, Tomokazu, ARAKAWA, Yoshiki, UEBA, Tetsuya, ODA, Masashi, NISHIDA, Namiko, AKIYAMA, Yukinori, TSUKAHARA, Tetsuya, IWASAKI, Koichi, MIKUNI, Nobuhiro, MIYAMOTO, Susumu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The Japan Neurosurgical Society 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5243161/
https://ncbi.nlm.nih.gov/pubmed/27725524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2176/nmc.oa.2016-0162
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller